

Indoco Remedies gets USFDA nod for Goa's sterile and solid dosage facilities

Mumbai, July 21: Indoco Remedies Ltd. has received approval from US drug regulator for its sterile facility (plant-II) and solid dosage facility (plant –III) located at Verna in Goa. The approval follows the inspection of both these facilities last year by the US Food and Drug Administration between August 22-30, 2013. With this approval, Indoco now has six of its facilities, approved by the USFDA. The six USFDA approved facilities include, three for Finished Dosages, two for APIs and one for Analytical.

“The approval will now facilitate the generic (ANDAs) approvals in the US market and subsequent product launches there. Without doubt, it will also boost the high-margin revenues of Indoco from the remunerative market of US and placing Indoco in the elite league with other International and Indian pharmaceutical companies,” said Suresh G. Kare, Chairman, Indoco Remedies Ltd.

The USFDA nod also assumes significance in the back-drop of media reports indicting on several pharmaceutical companies on compliance related issues.

Indoco Remedies, that derives 93% of its revenues from formulations and the balance through APIs, has export revenues worth 35% in its overall annual net revenue pie of Rs. 730 crore for the year ended March 31, 2014.

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with a global presence in 80 countries including USA and UK. Indoco, a USD 125 million Company, employs over 4500 people including 200 skilled scientists.

The Company has 8 manufacturing facilities, 5 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre. The facilities have been approved by UK-MHRA, USFDA, TGA-Australia, JAZMP-Slovenia, MCC-South Africa, Darmstadt – Germany, NDA-Uganda, TFDA-Tanzania, SBD-Yemen, MOH-Ukraine, PPB-Kenya, FDB-Ghana, etc. Indoco manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 2,00,000 doctors in India. Indoco's 8 domestic marketing divisions, viz., Indoco, Spade, Warren, Spera,

Excel, Eterna, Indoco CND and Institution cater to both acute and chronic therapies. Indoco has a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infectives, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, etc. Top Indoco brands include Febrex Plus, Cyclopam, Sensodent-K, ATM, Glychek, Methycal, Rosuchek-D, Omegachek, Vepan, Cital, Oxipod, Sensoform, Osteochek, Lorchek-MR, Homide, Renolen, Cloben-G, Karvol Plus, Tuspel Plus, Inflachek-D, Clamchek and MCBM 69. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) - USA, ASPEN-South Africa and DSM-Austria.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Kailash Rajwadkar

Mobile: 9869333999 / 9869111687

E-mail: kailash.rajwadkar@gmail.com

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com